BS_8T7DZV2F
medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- medulloblastoma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- medulloblastoma
- overall_survival_months
- 8.114323258869907
- age_years
- 15.375
- sex
- Female
GSVA pathway preview (0 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_KE56MMY0 | Neurofibroma | — | 0.926 |
| 2 | SRR934958 | — | — | 0.896 |
| 3 | 8B4E465B-0FD5-4154-824B-1E6B2656FD2F | — | — | 0.893 |
| 4 | F873381B-3D15-47B2-9385-080590B316B7 | — | — | 0.892 |
| 5 | SRR934839 | — | — | 0.889 |
| 6 | BS_0WQJP6ZG | Supratentorial Ependymoma | — | 0.888 |
| 7 | fca4c327-dfab-4455-84a8-f890a7326132 | — | — | 0.886 |
| 8 | SRR934965 | — | — | 0.886 |
| 9 | SRR934730 | — | — | 0.883 |
| 10 | 1B940F72-3C90-43C4-9267-185F21D10AC9 | — | — | 0.882 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 42 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V1 | 0.598 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.528 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.522 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.475 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.440 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.436 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.432 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.425 | Remibrutinib | — uncovered |
| ANGIOGENESIS | 0.376 | Remibrutinib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.324 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.323 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.316 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.312 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.295 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.294 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.288 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.287 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.285 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.274 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.274 | Inavolisib | — uncovered |